indapamide + perindopril + rosuvastatin

Indapamide + perindopril + rosuvastatin is a fixed-dose combination (FDC) therapy developed by Simpex Pharma for the management of cardiology patients presenting with both hypertension and hyperlipidemia. This small molecule combination integrates three distinct mechanisms of action: indapamide, a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule; perindopril, an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to the vasoconstrictor angiotensin II; and rosuvastatin, a statin that inhibits HMG-CoA reductase to lower LDL cholesterol levels. By combining these agents into a single tablet, the therapy aims to simplify treatment regimens and improve patient compliance in the management of cardiovascular risk factors.

Other names

Indapamide/perindopril/rosuvastatin